Viatris: A Cautionary Tale of the “Cheapest” Stock in the S&P 500

Viatris, currently the “cheapest” stock in the S&P 500 based on its earnings multiple, presents an intriguing case study in value investing. Despite trading at just 3.3 times earnings with a 5.1% dividend yield, only three out of eleven analysts covering the stock recommend buying it. This scenario prompts a deeper look into why such an ostensibly undervalued stock might not be the bargain it appears to be.

The Background of Viatris

Viatris emerged from the combination of Mylan, known for its controversial price hike of the EpiPen, and Upjohn, a unit of Pfizer. The company boasts a diverse portfolio, including generics, biosimilars, and brand-name drugs. Despite this, the stock has been on a downward trend, raising questions about its valuation.

Challenges and Investor Skepticism

The skepticism around Viatris stems from several factors:

1. Legal Challenges: Mylan’s EpiPen pricing controversy led to significant legal issues, affecting the reputation and trust in the new entity.

2. Market Competition: Viatris faces fierce competition in the biosimilars market, with heavyweights like Teva Pharmaceutical and AbbVie’s Humira potentially affecting its market share.

3. Strategic Decisions: Viatris’s decision to divest its biosimilars business, despite it being a potentially lucrative market in the coming years, has been met with mixed reactions.

4. Management’s Roadmap: While the company has a strategy to become a global leader in ophthalmology and offset its base business erosion, the execution and results of this plan are yet to be fully realized.

5. Financial Performance: Although Viatris projects significant free cash flow, the stock’s performance has not been encouraging. This discrepancy between earnings and stock value adds to investor hesitation.

The Investor’s Dilemma

Viatris’s situation highlights the complexity of value investing. While the stock appears cheap, the underlying challenges and market dynamics make it a potentially risky bet. The low valuation reflects market concerns about the company’s future earnings potential and the effectiveness of its turnaround strategy.